Evidence map›Paper›PMID 38847974›Full record

ReviewCurrent oncology reports2024

Current Status and Challenges in Rare Genitourinary Cancer Research and Future Directions.

Antonio Cigliola, Gagan Prakash, Roger Li, Karima Oualla, Shilpa Gupta, Ashish M Kamat, Jad Chahoud, Andrea Necchi, Philippe E Spiess

Erratum issuedAbstract readReview
PubMed Publisher
In one paragraph

Review in Current oncology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Antonio CigliolaDepartment of Medical Oncology, IRCCS San Raffaele Hospital, Via Olgettina 60, 20132, Milan, Italy. cigliola.antonio@hsr.it.
Gagan PrakashDepartment of Uro-Oncology, Tata Memorial Hospital, Mumbai, India.
Roger LiDepartment of GU Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Karima OuallaDepartment of Medical Oncology, Centre Hospitalier Universitaire Hassan II, Fes, Morocco.
Shilpa GuptaDepartment of Hematology and Medical Oncology, Cleveland Clinic Main Campus, Cleveland, OH, USA.
Ashish M KamatDepartment of Urology Under Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jad ChahoudDepartment of Uro-Oncology, Tata Memorial Hospital, Mumbai, India.
Andrea NecchiDepartment of Medical Oncology, IRCCS San Raffaele Hospital, Via Olgettina 60, 20132, Milan, Italy.
Philippe E SpiessDepartment of Uro-Oncology, Tata Memorial Hospital, Mumbai, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewIn contemporary urological practice, managing rare genitourinary (GU) malignancies presents significant challenges, necessitating a comprehensive understanding of their unique characteristics and tailored treatment approaches. RECENT

findingsRare GU malignancies, whether per se, variants of common histologies, or common tumors in uncommon locations, often lack widely available clinical guidelines. Consequently, treatment decisions are frequently based on empirical evidence, risking suboptimal outcomes. However, recent advances in molecular profiling, targeted therapies, and immunotherapy offer promising avenues for improving management strategies and patient outcomes. This review provides a comprehensive overview of some rare GU malignancies encountered in clinical practice, including their distinct pathological features, current management approaches, and ongoing research directions. Understanding the complexities of these rare tumors and implementing multidisciplinary treatment strategies are essential for optimizing patient care and improving survival outcomes.

Indexed as

Urogenital NeoplasmsHumansImmunotherapyMolecular Targeted TherapyRare DiseasesGenomic biomarkersHistologic subtypesNonurachal carcinomaPersonalized oncologyUrachal carcinoma

Identifiers

PMID38847974

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.